title: Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds.
abstract: OBJECTIVE
  Bioresorbable vascular scaffolds (BVS) have been available on the European market since November 2011. The ASSURE registry aims to investigate the safety and efficacy of the Absorb everolimus-eluting bioresorbable vascular scaffold in a real-world setting.
  
  
  RESULTS
  Patients with de novo coronary artery disease were consecutively enrolled at six German centres in this prospective registry. Outcomes were procedural success, cardiovascular death, myocardial infarction, and ischaemia-driven target lesion revascularisation (TLR). Angiographic parameters were assessed quantitatively and visual estimates of lesion dimensions were studied. One hundred and eighty-three patients were treated. In 128 (64.7%) lesions a complex ACC/AHA morphology was present. Procedural success was achieved in all patients. Acute gain was 1.54±0.51 mm, resulting in a final minimal lumen diameter (MLD), which met the baseline reference vessel diameter (RVD), although visual estimates overrated the RVD by 0.5±0.5 mm. Up to 12 months, one patient (0.5%) had died from gastrointestinal bleeding, three (1.7%) non-target vessel myocardial infarctions occurred, and five (2.8%) TLR had become necessary because of restenosis.
  
  
  CONCLUSIONS
  One-year results suggest that bioresorbable vascular scaffolds for de novo coronary artery disease are associated with favourable clinical and functional outcomes in routine clinical practice despite a visually overestimated RVD.
authors.affiliation: Department of Internal Medicine II, University of Ulm, Ulm, Germany.
authors.forename: Jochen
authors.initials: J
authors.lastname: Wöhrle
authors.forename: Christoph
authors.initials: C
authors.lastname: Naber
authors.forename: Thomas
authors.initials: T
authors.lastname: Schmitz
authors.forename: Carsten
authors.initials: C
authors.lastname: Schwencke
authors.forename: Norbert
authors.initials: N
authors.lastname: Frey
authors.forename: Christian
authors.initials: C
authors.lastname: Butter
authors.forename: Johannes
authors.initials: J
authors.lastname: Brachmann
authors.forename: Maja
authors.initials: M
authors.lastname: Ingwersen
authors.forename: Anna
authors.initials: A
authors.lastname: Drabik
authors.forename: Sinisa
authors.initials: S
authors.lastname: Markovic
authors.forename: Detlef G
authors.initials: DG
authors.lastname: Mathey
mesh_terms: D020341:Absorbable Implants; D000368:Aged; D000369:Aged, 80 and over; D002317:Cardiovascular Agents / Q000627:therapeutic use; D017023:Coronary Angiography / Q000379:methods; D003324:Coronary Artery Disease / Q000628:therapy*; D054855:Drug-Eluting Stents; D000068338:Everolimus / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D062645:Percutaneous Coronary Intervention / Q000379:methods; D011446:Prospective Studies; D012042:Registries; D054457:Tissue Scaffolds; D016896:Treatment Outcome
chemical_list: D002317:Cardiovascular Agents; D007166:Immunosuppressive Agents; D000068338:Everolimus